George Martin’s quote seems rather apt this morning as NextCure announced there was disappointing single agent activity with their Siglec–15 directed agent (NC318) in an ongoing phase 1/2 trial.

There were a couple of initial partial responses reported at SITC last year and now it may seem as if the wheels are falling off the wagon.

What can we learn from the latest update?

It turns out quite a bit…

To learn more from our oncology analysis and get a heads up on insights and commentary emerging from recent events, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Posted by